gaboxadol has been researched along with Depression, Involutional in 1 studies
gaboxadol: GABA agonist; inhibitor of GABA uptake systems; structure
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kasper, S | 1 |
| Ebert, B | 1 |
| Larsen, K | 1 |
| Tonnoir, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study of Escitalopram in Combination With Two Fixed Doses of Gaboxadol Compared to Escitalopram in Major Depressive Disorder[NCT00807248] | Phase 2 | 490 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00807248)
Timeframe: at Week 8
| Intervention | Scores on a scale (Mean) |
|---|---|
| Placebo (Orally, Once Daily) | 2.97 |
| Escitalopram 20 mg and Placebo (Orally, Once Daily) | 2.21 |
| Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily) | 2.35 |
| Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily) | 2.26 |
The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). (NCT00807248)
Timeframe: Mean change from baseline to Week 8
| Intervention | Scores on a scale (Mean) |
|---|---|
| Placebo (Orally, Once Daily) | -1.04 |
| Escitalopram 20 mg and Placebo (Orally, Once Daily) | -1.65 |
| Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily) | -1.58 |
| Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily) | -1.76 |
The HADS is a patient-rated scale designed to screen for anxiety and depressive states in medical patients. It consists of two sub-scales: the D-scale measures depression and the A-scale measures anxiety. Each sub-scale contains 7 items, and each item is rated from 0 (absent) to 3 (maximum severity). The score of each sub-scale ranges from 0 to 21, and are analysed separately. The total HADS score ranges from 0 to 42. (NCT00807248)
Timeframe: Mean change from baseline to Week 8
| Intervention | Scores on a scale (Mean) |
|---|---|
| Placebo (Orally, Once Daily) | -9.7 |
| Escitalopram 20 mg and Placebo (Orally, Once Daily) | -14.7 |
| Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily) | -14.1 |
| Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily) | -15.0 |
The ISI is both a brief screening measure of insomnia and an outcomes measure for use in treatment research. It is a brief self-report instrument measuring the patient's perception of his or her insomnia, and it comprises 7 items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28. 0 = no symptoms and 28 = severe symptoms. (NCT00807248)
Timeframe: Mean change from baseline to Week 8
| Intervention | Scores on a scale (Mean) |
|---|---|
| Placebo (Orally, Once Daily) | -6.9 |
| Escitalopram 20 mg and Placebo (Orally, Once Daily) | -10.0 |
| Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily) | -9.6 |
| Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily) | -10.6 |
The MADRS is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at 2-point intervals. The total score of the 10 items ranges from 0 to 60. (NCT00807248)
Timeframe: From baseline to Week 8
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo (Orally, Once Daily) | -13.4 |
| Escitalopram 20 mg and Placebo (Orally, Once Daily) | -19.0 |
| Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily) | -18.5 |
| Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily) | -19.4 |
The MADRS is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at 2-point intervals. The total score of the 10 items ranges from 0 to 60. (NCT00807248)
Timeframe: Baseline to 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Placebo (Orally, Once Daily) | -13.4 |
| Escitalopram 20 mg and Placebo (Orally, Once Daily) | -19.0 |
| Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily) | -18.5 |
| Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily) | -19.4 |
The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. (NCT00807248)
Timeframe: Mean change from baseline to Week 8
| Intervention | Scores on a scale (Mean) |
|---|---|
| Placebo (Orally, Once Daily) | -2.7 |
| Escitalopram 20 mg and Placebo (Orally, Once Daily) | -3.9 |
| Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily) | -3.8 |
| Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily) | -4.1 |
The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. (NCT00807248)
Timeframe: Mean change from baseline to Week 8
| Intervention | Scores on a scale (Mean) |
|---|---|
| Placebo (Orally, Once Daily) | -2.7 |
| Escitalopram 20 mg and Placebo (Orally, Once Daily) | -3.8 |
| Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily) | -3.8 |
| Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily) | -4.0 |
The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. (NCT00807248)
Timeframe: Mean change from baseline to Week 8
| Intervention | Scores on a scale (Mean) |
|---|---|
| Placebo (Orally, Once Daily) | -2.8 |
| Escitalopram 20 mg and Placebo (Orally, Once Daily) | -4.0 |
| Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily) | -3.9 |
| Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily) | -4.1 |
1 trial available for gaboxadol and Depression, Involutional
| Article | Year |
|---|---|
Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.
Topics: Adolescent; Adult; Aged; Analgesics; Analysis of Variance; Antidepressive Agents, Second-Generation; | 2012 |